166 related articles for article (PubMed ID: 4086244)
1. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON).
Rahman A; Smith FP; Luc PT; Woolley PV
Invest New Drugs; 1985; 3(4):369-74. PubMed ID: 4086244
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff RB; Casper ES; Magill GB; Young CW
Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Earhart RH; Amato DJ; Chang AY; Borden EC; Shiraki M; Dowd ME; Comis RL; Davis TE; Smith TJ
Invest New Drugs; 1990 Feb; 8(1):113-9. PubMed ID: 2188926
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic studies of DON.
Kovach JS; Eagan RT; Powis G; Rubin J; Creagan ET; Moertel CG
Cancer Treat Rep; 1981; 65(11-12):1031-6. PubMed ID: 7296548
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON).
Kulkarni RM; Dakoulas EW; Miller KE; Terse PS
Toxicol Mech Methods; 2017 Sep; 27(7):518-527. PubMed ID: 28552037
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
[No Abstract] [Full Text] [Related]
10. Inhibition of tooth germ differentiation in vitro by diazo-oxo-norleucine (DON).
Hurmerinta K; Thesleff I; Saxén L
J Embryol Exp Morphol; 1979 Apr; 50():99-109. PubMed ID: 458364
[TBL] [Abstract][Full Text] [Related]
11. The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
Kisner DL; Catane R; Muggia FM
Recent Results Cancer Res; 1980; 74():258-63. PubMed ID: 7192426
[TBL] [Abstract][Full Text] [Related]
12. Mutagenicity of O-diazoacetyl-L-serine (azaserine) and 6-diazo-5-oxo-L- norleucine (DON) in a soybean test system.
Katoh Y; Maekawa M; Sano Y
Mutat Res; 1995 Mar; 342(1-2):37-41. PubMed ID: 7885392
[TBL] [Abstract][Full Text] [Related]
13. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
14. L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.
Ohba S; Hirose Y
J Neurooncol; 2020 Feb; 146(3):469-475. PubMed ID: 32020477
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
[TBL] [Abstract][Full Text] [Related]
16. Studies of DNA damage in rat pancreas and liver by 6-diazo-5-oxo-L-norleucine, ethyl diazoacetate and azaserine.
Lilja HS; Longnecker DS; Curphey TJ; Daniel DS; Adams WE
Cancer Lett; 1981 Mar; 12(1-2):139-46. PubMed ID: 7272997
[TBL] [Abstract][Full Text] [Related]
17. Effects of diazo-oxo-norleucine on cell kinetics and odontoblast differentiation in cultured embryonic mouse molars.
Olive M; Ruch JV
Arch Oral Biol; 1982; 27(6):505-11. PubMed ID: 6956264
[TBL] [Abstract][Full Text] [Related]
18. Influence of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue, on cartilaginous differentiation in mouse limb buds in vitro.
Aydelotte MB; Kochhar DM
Differentiation; 1975 Oct; 4(2):73-80. PubMed ID: 1183764
[TBL] [Abstract][Full Text] [Related]
19. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
Willis RC; Seegmiller JE
J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
[TBL] [Abstract][Full Text] [Related]
20. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
